Dactinomycin D

放线菌素D

Report date: 2025/12/22 15:39:59
NME

Base Information

Drug NameDactinomycin D
Drug Alias Name更生霉素dactinomycinumD放线菌素Dactinomycin放线霉素D +[10] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionDNA inhibitors
TargetsDNA
Therapy Area/IndicationsSolid tumoursTesticular NeoplasmsHydatidiform Mole +[11] 
Global Approved IndicationsSolid tumoursTesticular NeoplasmsGestational Trophoblastic Disease +[9] 
Approved Indications in ChinaTesticular NeoplasmsChoriocarcinomaNeuroblastoma +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date1964/12/10
Country/TerritoryCanadaUnited StatesNorway +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRecordati
China Registration ClassN/A

Develop Information

Active CompaniesShaanxi Wuzhou Pharmaceutical Co Ltd
Inactive CompaniesGog Foundation IncRecordati Rare Diseases IncNational Cancer Institute
Active IndicationsTesticular NeoplasmsChoriocarcinomaNeuroblastoma +[5] 
Inactive IndicationsSolid tumoursHydatidiform MoleGestational Trophoblastic Disease +[6] 

Other Information

ATC CodeL01DA01
Related LinksWikipediaDrugBankKEGG